Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | CA4 | P22748 | 3/20 | 0.41 |
| ▸ | CA5A | P35218 | 3/20 | 0.41 |
| ▸ | CA7 | P43166 | 3/20 | 0.41 |
| ▸ | CA9 | Q16790 | 3/20 | 0.41 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.41 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.36 |
| ▸ | PDE4A | P27815 | 3/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CRHBP | P24387 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5089500 | 0.85 | CYP1A2 (0.55) | CYP1A2GAASMN1; SMN2CA2CA12 | |
| SCHEMBL12494506 | 0.85 | CYP1A2 (0.55) | CYP1A2GAASMN1; SMN2CA2CA12 | |
| SCHEMBL1716076 | 0.84 | CYP1A2 (0.62) | CYP1A2GAASMN1; SMN2CA2CA12 | |
| SCHEMBL547427 | 0.83 | CYP1A2 (0.50) | CYP1A2GAASMN1; SMN2CA2CA12 | |
| SCHEMBL548039 | 0.83 | CYP1A2 (0.50) | CYP1A2GAASMN1; SMN2CA2CA12 | |
| SCHEMBL3658921 | 0.82 | CYP1A2 (0.59) | CYP1A2GAASMN1; SMN2CA2CA12 | |
| SCHEMBL11893308 | 0.82 | CYP1A2 (0.51) | CYP1A2GAASMN1; SMN2CA2CA12 | |
| SCHEMBL12493846 | 0.80 | CYP1A2 (0.47) | CYP1A2GAASMN1; SMN2CA2CA12 | |
| SCHEMBL1715829 | 0.80 | CYP1A2 (0.53) | CYP1A2GAASMN1; SMN2CA2CA12 | |
| SCHEMBL547624 | 0.79 | CYP1A2 (0.46) | CYP1A2GAASMN1; SMN2CA2CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3357917-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2018-08-08 | — | — | EP | disclosed |
| US-10023556-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023556-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2018-07-17 | — | — | US | disclosed |
| EP-3124481-B1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-3124481-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | Aragon Pharmaceuticals, Inc. (US) | 2017-02-01 | — | — | EP | disclosed |
| EP-2824102-B1 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS INC (US) | 2017-02-01 | — | — | EP | disclosed |
| US-20160376252-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-9481664-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-9108944-B2 | Androgen receptor modulators and uses thereof | ARAGON PHARMACEUTICALS, INC. (US) | 2015-08-18 | — | — | US | disclosed |
| US-20150182529-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS INC (US) | 2015-07-02 | — | — | US | disclosed |
| EP-2824102-A1 | Androgen receptor modulators and uses thereof | Aragon Pharmaceuticals, Inc. (US) | 2015-01-14 | — | — | EP | disclosed |
| US-20130116258-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | ARAGON PHARMACEUTICALS, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116258-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | AR, ESRRA, NR5A1 | CYP1A2 767/4885GAA 3086/4885SMN1; SMN2 4730/4885 |
| US-20150182529-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | AR, ESRRA, NR5A1 | CYP1A2 767/4885GAA 3086/4885SMN1; SMN2 4730/4885 |
| US-10023556-B2 | Androgen receptor modulators and uses thereof | AR, ESRRA, NR5A1 | CYP1A2 767/4885GAA 3086/4885SMN1; SMN2 4730/4885 |
| US-20160376252-A1 | ANDROGEN RECEPTOR MODULATORS AND USES THEREOF | AR, ESRRA, NR5A1 | CYP1A2 767/4885GAA 3086/4885SMN1; SMN2 4730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.